Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Marit

Showing results (101-110 of 107) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 107 results.
Leukemia|March 1, 1996
A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75J Reiffers, F Huguet, A M Stoppa, et al.
Leukemia|August 10, 2012
Minor clone provides a reservoir for relapse in multiple myelomaF Magrangeas, H Avet-Loiseau, W Gouraud, et al.
Leukemia|April 5, 2017
Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trialN J Bahlis, A Corso, L-O Mugge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2000
Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantationI Yakoub-Agha, P de La Salmonière, P Ribaud, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 21, 2016
Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myelomaG Fouquet, B Pegourie, M Macro, et al.
Leukemia|July 13, 2007
Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trialsP Moreau, M Attal, F Garban, et al.
Leukemia|July 30, 2013
Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patientsB Hebraud, X Leleu, V Lauwers-Cances, et al.
Pageof 11

Showing results (101-110 of 107) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 107 results.
Leukemia|March 1, 1996
A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75J Reiffers, F Huguet, A M Stoppa, et al.
Leukemia|August 10, 2012
Minor clone provides a reservoir for relapse in multiple myelomaF Magrangeas, H Avet-Loiseau, W Gouraud, et al.
Leukemia|April 5, 2017
Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trialN J Bahlis, A Corso, L-O Mugge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2000
Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantationI Yakoub-Agha, P de La Salmonière, P Ribaud, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 21, 2016
Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myelomaG Fouquet, B Pegourie, M Macro, et al.
Leukemia|July 13, 2007
Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trialsP Moreau, M Attal, F Garban, et al.
Leukemia|July 30, 2013
Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patientsB Hebraud, X Leleu, V Lauwers-Cances, et al.
Pageof 11